2788sek
-0,3 %
Date:2024-04-24Time:17:29:55Latest report:Q1-2024List:Mid CapTicker:HNSA
Market Cap:1 826 msekEnterprise Value:2 232 msekNet Sales:165,9 msekEarnings:-844,9 msekEmployees:0ISIN:SE0002148817

Ratios

10-year key figure history for Hansa Biopharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Hansa Biopharma with index and moving average MA50 and MA200.

Stockprice:27,88
MA50:30,61
MA200:33,28
Price/MA200:-16,2 %
RSI (14):38,9
Price/MA50:-8,9 %

Description

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Biotechnology